DNA & Genetics Intellia Shares Sink as Clinical Hold Follows Safety SetbackBy adminNovember 2, 20250 John Leonard, MD, Intellia Therapeutics president and CEO Addressing analysts in August, Intellia Therapeutics (NASDAQ: NTLA) president and CEO John…
